Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii

Forty-six patients were treated with eravacycline (ERV) for Acinetobacter baumannii infections, where 69.5% of isolates were carbapenem resistant (CRAB). Infections were primarily pulmonary (58.3%), and most patients received combination therapy (84.4%). The median (IQR) ERV duration was 6.9 days (5...

Descripción completa

Detalles Bibliográficos
Autores principales: Alosaimy, Sara, Morrisette, Taylor, Lagnf, Abdalhamid M., Rojas, Leonor M., King, Madeline A., Pullinger, Benjamin M., Hobbs, Athena L. V., Perkins, Nicholson B., Veve, Michael P., Bouchard, Jeannette, Gore, Tristan, Jones, Bruce, Truong, James, Andrade, Justin, Huang, Glen, Cosimi, Reese, Kang-Birken, S. Lena, Molina, Kyle C., Biagi, Mark, Pierce, Michael, Scipione, Marco R., Zhao, Jing J., Davis, Susan L., Rybak, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602915/
https://www.ncbi.nlm.nih.gov/pubmed/36190427
http://dx.doi.org/10.1128/spectrum.00479-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602915/
https://www.ncbi.nlm.nih.gov/pubmed/36190427
http://dx.doi.org/10.1128/spectrum.00479-22

Ejemplares similares